AOTMiT: What will the Transparency Council address on February 16?

The agenda includes:

1. Preparation of a position paper on the qualification of the health care benefit "Parathyroid Biopsy".
2. Preparation of a position paper on the evaluation of the drug Blenrep (belantamab mafodotin) under drug program B.54 "Treatment of patients with plasmocytic myeloma".
3. Preparation of a position paper on examining the appropriateness of issuing reimbursement approvals for the medicinal product Tyrvaya (varenicline solution) for the indication: dry eye syndrome.
4. Preparation of a position paper on the examination of the legitimacy of issuing approvals for reimbursement of the medicinal products Tript-OH and Levotonine containing the active substance L-5-hydroxytryptophan for the indication: tetrahydrobiopterin deficiencies.
5. Preparation of an opinion on the active substance blinatumomab for the off-label indication: treatment with blinatumomab in the consolidation phase in the first-line treatment of pediatric patients with newly diagnosed high-risk acute lymphoblastic leukemia.

Source: AOTMiT